Mary Ruisi
About
Mary Ruisi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Mary Ruisi has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Mary Ruisi's work include Cancer Immunotherapy and Biomarkers (16 papers), CAR-T cell therapy research (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Mary Ruisi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), CAR-T cell therapy research (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Mary Ruisi collaborates with scholars based in United States, Germany and France. Mary Ruisi's co-authors include Marcis Bajars, David R. Spigel, Mustafa Özgüroğlu, Johan Vansteenkiste, Hidenobu Ishii, Andreas Polychronis, Maciej Krzakowski, Keunchil Park, Jong Seok Lee and Fabrice Barlési and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.
In The Last Decade
Mary Ruisi
28 papers receiving 1.1k citations
Hit Papers
Peers
Mary Ruisi
Jiajia Zhang United States
Seong Hyun Jeong South Korea
Ramesh Kumar Pandey United States
J.M. Tourani France
Kartik Sehgal United States
Nicoletta Pella Italy
Michael Doukas Netherlands
Jurjen Versluis Netherlands
Bettina Bisig Switzerland
D Schlaifer France
Citations per year, relative to Mary Ruisi Mary Ruisi (= 1×)
peers
Jiajia Zhang
Countries citing papers authored by Mary Ruisi
Since
Specialization
Citations
This map shows the geographic impact of Mary Ruisi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Ruisi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Ruisi more than expected).
Fields of papers citing papers by Mary Ruisi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mary Ruisi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Ruisi. The network helps show where Mary Ruisi may publish in the future.
Co-authorship network of co-authors of Mary Ruisi
This figure shows the co-authorship network connecting the top 25 collaborators of Mary Ruisi. A scholar is included among the top collaborators of Mary Ruisi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Ruisi. Mary Ruisi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
D’Alessandro, Claudia, Domenico Giannese, Mary Ruisi, et al.. (2024). Nutrition and Physical Activity in Older Adults with CKD: Two Sides of the Same Coin. Kidney & Blood Pressure Research. 49(1). 978–986.
2.
Carneiro, Benedito A., Meredith McKean, Cécile Vicier, et al.. (2024). A phase 1/1b, first-in-human, multi-part study of DF6215, an engineered IL-2Rα-active agonist, to investigate the safety, tolerability, pharmacokinetics, and biological and clinical activity in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS2704–TPS2704.
3.
Louie, Thomas, Yoav Golan, Sahil Khanna, et al.. (2023). VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection. JAMA. 329(16). 1356–1356.
4.
Vugmeyster, Yulia, et al.. (2022). Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors. Clinical Pharmacokinetics. 61(7). 985–995.
5.
Loeb, David M., Ji Won Lee, Daniel A. Morgenstern, et al.. (2022). Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial. Cancer Immunology Immunotherapy. 71(10). 2485–2495.
6.
Menon, Rajita, Emily Crossette, Shakti K. Bhattarai, et al.. (2022). 890: RAPID AND DURABLE COLONIZATION OF VE303 IN CLOSTRIDIODES DIFFICILE INFECTION (CDI) PATIENTS IS ASSOCIATED WITH CLINICAL EFFICACY: RESULTS OF THE PHASE 2 CONSORTIUM STUDY. Gastroenterology. 162(7). S–217.
7.
Park, Keunchil, Mustafa Özgüroğlu, Johan Vansteenkiste, et al.. (2021). Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. Journal of Thoracic Oncology. 16(8). 1369–1378.
8.
Park, Keunchil, Mustafa Özgüroğlu, Johan Vansteenkiste, et al.. (2021). Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial. Lung Cancer. 154. 92–98.
9.
Grote, H., Zheng Feng, Michael Schlichting, et al.. (2020). Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay. Journal of Thoracic Oncology. 15(8). 1306–1316.
10.
Barlési, Fabrice, Mustafa Özgüroğlu, Johan Vansteenkiste, et al.. (2019). Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC). Annals of Oncology. 30. v611–v612.
11.
Ruisi, Mary, et al.. (2019). Markedly Reduced Expression of Annexin A2 Is Associated with Hypofibrinolysis and Provoked and Unprovoked Venous Thromboembolism. Blood. 134(Supplement_1). 443–443.
12.
Barlési, Fabrice, Johan Vansteenkiste, David R. Spigel, et al.. (2018). Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. The Lancet Oncology. 19(11). 1468–1479.
13.
Rajan, Arun, James L. Gulley, David R. Spigel, et al.. (2018). Avelumab (anti–PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial.. Journal of Clinical Oncology. 36(15_suppl). 9090–9090.
14.
Barlési, Fabrice, Johan Vansteenkiste, David R. Spigel, et al.. (2018). OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial. Journal of Thoracic Oncology. 13(10). S331–S332.
15.
Weber, Jeffrey S., Ryan J. Sullivan, Jeffrey A. Sosman, et al.. (2016). Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. The Lancet Oncology. 17(7). 943–955.
16.
Rodig, Scott J., Evisa Gjini, Chelsea Jin, et al.. (2016). Abstract CT133: Association of programmed death-ligand 1 (PD-L1) and 2 (PD-L2) expression with nivolumab (NIVO) efficacy in advanced melanoma (MEL). Cancer Research. 76(14_Supplement). CT133–CT133.
17.
Weber, Jeffrey S., Jean‐Jacques Grob, Kim Margolin, et al.. (2015). A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence. Journal for ImmunoTherapy of Cancer. 3(S2).
18.
Spencer, Kristen, Mary Ruisi, Nageatte Ibrahim, et al.. (2014). Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. Journal for ImmunoTherapy of Cancer. 2(1). 33–33.
19.
Barsam, Sarah, Bethan Psaila, Marc Forestier, et al.. (2011). Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood. 117(21). 5723–5732.
20.
Ruisi, Mary, Daniel J. Green, Benjamin T. Kile, et al.. (2010). Radioulnar Synostosis and Its Hematology and Genetic Associations. Blood. 116(21). 2521–2521.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jiajia Zhang Breakdown of academic impact, for papers by Seong Hyun Jeong Breakdown of academic impact, for papers by Ramesh Kumar Pandey Breakdown of academic impact, for papers by J.M. Tourani Breakdown of academic impact, for papers by Kartik Sehgal Breakdown of academic impact, for papers by Nicoletta Pella Breakdown of academic impact, for papers by Michael Doukas Breakdown of academic impact, for papers by Jurjen Versluis Breakdown of academic impact, for papers by Bettina Bisig Breakdown of academic impact, for papers by D Schlaifer